中国科学院机构知识库网格系统: 检索

浏览/检索结果: 共5条，第1-5条

帮助

条数/页：排序方式：
	Anlotinib plus Docetaxel versus Docetaxel as 2nd Line Treatment in Advanced Non-Small Cell Lung Cancer: A Phase I/II Study 期刊论文 OAI收割 JOURNAL OF THORACIC ONCOLOGY, 2021, 卷号: 16 作者: Fang, Y.; Pan, H.; Shou, J.; Hong, W.; Yang, X. \| 收藏 \| 浏览/下载：32/0 \| 提交时间：2021/05/17 Anlotinib NSCLC anti-angiogenesis
	Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China 期刊论文 OAI收割 CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021 作者: Zhang, Xiangyu; Zeng, Liang; Li, Yizhi; Xu, Qinqin; Yang, Haiyan \| 收藏 \| 浏览/下载：44/0 \| 提交时间：2021/03/15 Anlotinib Immunotherapy Programmed death 1 inhibitor Lung cancer
	Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species 期刊论文 OAI收割 ACTA PHARMACOLOGICA SINICA, 2018, 卷号: 39, 期号: 6, 页码: 1048-1063 作者: Zhong, Chen-chun; Chen, Feng; Yang, Jun-ling; Jia, Wei-wei; Li, Li \| 收藏 \| 浏览/下载：54/0 \| 提交时间：2019/01/08 anlotinib tyrosine kinase inhibitor absorption distribution metabolism excretion pharmacokinetics
	Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor 期刊论文 OAI收割 CANCER SCIENCE, 2018, 卷号: 109, 期号: 4, 页码: 1207-1219 作者: Xie, Chengying; Wan, Xiaozhe; Quan, Haitian; Zheng, Mingyue; Fu, Li \| 收藏 \| 浏览/下载：57/0 \| 提交时间：2019/01/08 angiogenesis anlotinib tyrosine kinase inhibitor VEGF VEGFR2
	Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors 期刊论文 OAI收割 JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 卷号: 9 作者: Sun, Yongkun; Niu, Wei; Du, Feng; Du, Chunxia; Li, Shuting \| 收藏 \| 浏览/下载：55/0 \| 提交时间：2019/01/08 Anlotinib Anti-angiogenesis Phase I study Advanced refractory solid tumors Pharmacokinetics Safety